Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Valentina Guarneri, Vittorio Gebbia et al.|Journal of Clinical Oncology|2023Cited by 25
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast CancerMaria Vittoria Dieci, Valentina Guarneri, Giancarlo Bisagni et al.|JAMA Oncology|2025Cited by 17
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus projectStefania Gori, Paolo Tralongo, Fiorenza De Rose et al.|Cancer Treatment Reviews|2024Cited by 2